BrainStorm Cell Therapeutics Inc. (BCLI) shareholders
BCLIOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.77−0.01 (-1.17%)
Close on Oct 19, 2026Market cap $8.50MP/E –Yield –
Ownership
Institutional holdings as of Dec 31, 2025, from 13F filings
Held by institutions
0.0%
0M of 11M shares
Institutional holders
0
0 new, 5 sold out
Net institutional buying
-0M
In Q4 2025
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Kevin D. Ness | 3,060,000 | 6.25% | 13G (passive) amendment | Feb 12, 2024 |
| Armistice Capital, LLC Joint filing with Steven Boyd (9.99%) | 717,500 | 9.99% | 13G (passive) | Mar 31, 2025 |
| Matthew J. Ruck | 275,838 | 5.18% | 13G (passive) | Nov 13, 2024 |
Top institutional holders
13F holdings as of Sep 30, 2025
| Holder | Shares | % of BCLI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Osaic Holdings, Inc. | 1,785 | 0.02% | $1.35K | – | 0.00% |
| Bangor Savings Bank | 266 | 0.00% | $188 | – | 0.00% |
| VSM Wealth Advisory, LLC | 120 | 0.00% | $85 | – | 0.00% |
| Steward Partners Investment Advisory, LLC | 113 | 0.00% | $80 | – | 0.00% |
| St Germain D J Co Inc | 33 | 0.00% | $23 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q4 2025 | 0 | 0M | 0.0% | 0 / 0 | 0 / 5 | 0M | 0M |
| Q3 2025 | 5 | 0M | 0.0% | 0 / 0 | 0 / 29 | 0M | 0M |
| Q2 2025 | 34 | 0M | 3.6% | 7 / 4 | 3 / 5 | 0M | 1M |
| Q1 2025 | 32 | 1M | 9.3% | 7 / 7 | 3 / 6 | 1M | 0M |
| Q4 2024 | 31 | 0M | 3.3% | 28 / 0 | 1 / 1 | 0M | 0M |
| Q3 2024 | 4 | 0M | 0.1% | 4 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Peter Joe Pitts | Executive Chairman, Director | – | – | Jul 28, 2026 |
| Uri Yablonka | EVP & Chief Business Officer, Director | 218,464 | 1.98% | May 29, 2026 |
| Alla Patlis | See Remarks | 144,349 | 1.31% | May 29, 2026 |
| Chaim Lebovits | President & CEO | 2,134,349 | 19.34% | May 29, 2026 |
| Jacob A. Frenkel | Director | 343,777 | 3.12% | Jul 28, 2026 |
| Irit Arbel | Director | 161,054 | 1.46% | May 29, 2026 |
| Ibrahim B. Dagher | Director | 79,515 | 0.72% | May 20, 2026 |
| Nir Naor | Director | 31,465 | 0.29% | May 20, 2026 |
| Anthony J. Polverino | Director | 25,730 | 0.23% | May 20, 2026 |
| Menghisteab Bairu | Director | 24,000 | 0.22% | May 20, 2026 |
| Hartoun Hartounian | Director | 52,000 | 0.47% | May 20, 2026 |
| Stacy Lindborg | Director | 48,229 | 0.44% | May 20, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jacob A. Frenkel Director | Jul 24, 2026 | Award | +100,000 | – | – | 343,777 |
| Chaim Lebovits President & CEO | Feb 26, 2026 | Award | +1,800,000 | – | – | 2,000,960 |
| Alla Patlis See Remarks | Feb 26, 2026 | Award | +100,000 | – | – | 144,349 |
| Irit Arbel Director | Feb 26, 2026 | Award | +120,000 | – | – | 161,054 |
| Uri Yablonka EVP & Chief Business Officer, Director | Feb 26, 2026 | Award | +150,000 | – | – | 218,464 |
| Jacob A. Frenkel Director | Feb 26, 2026 | Award | +200,000 | – | – | 243,777 |
| Ibrahim B. Dagher Chief Medical Officer | Jan 1, 2025 | Award | +50,000 | – | – | 66,849 |
| Anthony J. Polverino Director | Jan 1, 2025 | Award | +24,000 | – | – | 25,730 |
| Alla Patlis See Remarks | Jan 1, 2025 | Award | +40,000 | – | – | 44,349 |
| Jacob A. Frenkel Director | Jan 1, 2025 | Award | +40,000 | – | – | 43,777 |
| Menghisteab Bairu Director | Jan 1, 2025 | Award | +24,000 | – | – | 24,000 |
| Nir Naor Director | Jan 1, 2025 | Award | +30,666 | – | – | 31,465 |
| Stacy Lindborg Director | Jan 1, 2025 | Award | +20,000 | – | – | 48,229 |
| Uri Yablonka EVP & Chief Business Officer, Director | Jan 1, 2025 | Award | +20,000 | – | – | 68,464 |
| Uri Yablonka EVP & Chief Business Officer, Director | Jan 1, 2025 | Award | +40,000 | – | – | 48,464 |
| Irit Arbel Director | Jan 1, 2025 | Award | +30,666 | – | – | 41,054 |
| Chaim Lebovits President & CEO | Jan 1, 2025 | Award | +120,000 | – | – | 200,960 |
| Hartoun Hartounian EVP, Chief Operating Officer | Jan 1, 2025 | Award | +50,000 | – | – | 52,000 |
| Chaim Lebovits President & CEO | Oct 1, 2024 | Buy | +1,836 | $3.43 | $6.30K | 80,960 |
| Chaim Lebovits President & CEO | Sep 30, 2024 | Buy | +22,000 | $0.23 | $5.06K | 1,186,865 |
| Ibrahim B. Dagher Chief Medical Officer | Jul 19, 2024 | Sale | −63,000 | $0.35 | $22.05K | 0 |
| Hartoun Hartounian EVP, Chief Operating Officer | Jun 24, 2024 | Award | +30,000 | – | – | 30,000 |
| Chaim Lebovits President & CEO | May 28, 2024 | Buy | +15,000 | $0.52 | $7.80K | 1,164,865 |
| Chaim Lebovits President & CEO | May 28, 2024 | Award | +15,000 | $0.52 | $7.80K | 1,164,865 |
| Chaim Lebovits President & CEO | May 22, 2024 | Buy | +25,000 | $0.64 | $16.00K | 1,149,865 |
| Chaim Lebovits President & CEO | May 22, 2024 | Award | +25,000 | $0.64 | $16.00K | 1,149,865 |
| Chaim Lebovits President & CEO | May 21, 2024 | Buy | +25,000 | $0.58 | $14.50K | 1,124,865 |
| Chaim Lebovits President & CEO | May 21, 2024 | Award | +25,000 | $0.58 | $14.50K | 1,124,865 |
| Chaim Lebovits President & CEO | May 13, 2024 | Buy | +10,000 | $0.49 | $4.90K | 1,099,865 |
| Chaim Lebovits President & CEO | May 13, 2024 | Award | +10,000 | $0.49 | $4.90K | 1,099,865 |
| Chaim Lebovits President & CEO | May 11, 2024 | Buy | +10,000 | $0.47 | $4.70K | 1,089,865 |
| Chaim Lebovits President & CEO | May 11, 2024 | Award | +10,000 | $0.47 | $4.70K | 1,089,865 |
| Chaim Lebovits President & CEO | May 10, 2024 | Buy | +20,000 | $0.47 | $9.40K | 1,079,865 |
| Chaim Lebovits President & CEO | May 10, 2024 | Award | +20,000 | $0.47 | $9.40K | 1,079,865 |
| Chaim Lebovits President & CEO | May 7, 2024 | Buy | +66,300 | $0.37 | $24.53K | 1,059,865 |
| Chaim Lebovits President & CEO | May 7, 2024 | Award | +66,300 | $0.37 | $24.53K | 1,059,865 |
| Chaim Lebovits President & CEO | May 6, 2024 | Buy | +135,000 | $0.38 | $51.30K | 993,565 |
| Chaim Lebovits President & CEO | May 6, 2024 | Award | +135,000 | $0.38 | $51.30K | 993,565 |
| Chaim Lebovits President & CEO | Apr 19, 2024 | Buy | +15,000 | $0.52 | $7.80K | 858,565 |
| Chaim Lebovits President & CEO | Apr 19, 2024 | Award | +15,000 | $0.52 | $7.80K | 858,565 |
| Chaim Lebovits President & CEO | Apr 18, 2024 | Buy | +115,072 | $0.53 | $60.99K | 843,565 |
| Chaim Lebovits President & CEO | Apr 18, 2024 | Award | +115,072 | $0.53 | $60.99K | 843,565 |
| Chaim Lebovits President & CEO | Apr 17, 2024 | Buy | +130,000 | $0.55 | $71.50K | 728,493 |
| Chaim Lebovits President & CEO | Apr 17, 2024 | Award | +130,000 | $0.55 | $71.50K | 728,493 |
| Stacy Lindborg Co-Chief Executive Officer | Mar 11, 2024 | Award | +241,935 | – | – | 423,435 |
| Alla Patlis See Remarks | Mar 11, 2024 | Award | +65,246 | – | – | 65,246 |
| Chaim Lebovits President & CEO | Mar 11, 2024 | Award | +305,198 | – | – | 598,493 |
| Uri Yablonka EVP & Chief Business Officer, Director | Mar 11, 2024 | Award | +109,426 | – | – | 126,969 |
| Stacy Lindborg Co-Chief Executive Officer | Sep 1, 2023 | Buy | +11,500 | $1.77 | $20.36K | 181,500 |
| Stacy Lindborg Co-Chief Executive Officer | Aug 2, 2023 | Award | +35,000 | – | – | 170,000 |
| Chaim Lebovits President & CEO | Aug 2, 2023 | Award | +31,185 | – | – | 293,295 |
| Nir Naor Director | Jun 19, 2023 | Award | +11,999 | – | – | 11,999 |
| Kirk Taylor Chief Medical Officer | May 1, 2023 | Award | +35,000 | – | – | 35,000 |
| Chaim Lebovits President & Co-CEO | Apr 20, 2023 | Award | +75,000 | – | – | 262,110 |
| Stacy Lindborg Co-Chief Executive Officer | Apr 20, 2023 | Award | +75,000 | – | – | 135,000 |
| Stacy Lindborg Co-Chief Executive Officer | Dec 7, 2022 | Award | +35,000 | – | – | 60,000 |
| Chaim Lebovits Chief Executive Officer | Sep 18, 2022 | Award | +31,185 | – | – | 187,110 |
| Ralph Dr. Kern COO and Chief Medical Officer | Mar 6, 2022 | Award | +35,885 | – | – | 223,310 |
| Anthony J. Polverino Director | Feb 1, 2022 | Award | +3,882 | – | – | 25,960 |
| Malcolm S. Taub Director | Dec 15, 2021 | Award | +12,000 | – | – | 77,332 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
2.0
At 0M shares a day
Change since last report
+76.9%
From 0M shares
Short volume, 20 days
58.2%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of BrainStorm Cell Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 4,962 shares on Aug 19, 2026 over the last 90 days.
See a number that looks wrong?